Piramal acquires blood plasma range from PlasmaSelect
This article was originally published in Scrip
Piramal Healthcareof India has completed a definitive agreement with PlasmaSelect of Germany to acquire PlasmaSelect’s polygeline-based blood plasma products (marketed as Haemaccel) for €7.7 million. Piramal Healthcare (previously Nicholas Piramal) expects to build a leadership position in polygeline-based blood plasma expansion products through the acquisition.
The transaction includes the brand rights, contracts, registrations, dossiers and know-how relating to Haemaccel and associated brands. However, it excludes PlasmaSelect's manufacturing facility in Marburg, Germany.
Piramal is settingup a new EDQM and UK MHRA-compliant facility for Haemaccel in Baddi, India, with an initial capacity of 4.2 million units. PlasmaSelect will continue to manufacture Haemaccel as per Piramal'srequirements to facilitate the migration of manufacturing to the new plant in India. Blood plasma expansion products are life-saving infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss.
Haemaccel is marketed in more than 38 countries and also available as Emagel in Italy and Solucel in Venezuela. Piramal currently markets the products as Haemaccel in India and as Haemageline in 17 other countries. In 1998, Piramal Healthcare acquired the Haemaccel-related business in India along with the manufacturing facility in Mumbai from Sanofi-Aventis. In 2004, PlasmaSelect acquired the Haemaccel-related rights in 76 countries and its manufacturing facility in Marburg from Sanofi-Aventis. Annual revenues of Haemaccel and associated brands of Piramal Healthcare and PlasmaSelect together are estimated at €9.1 million.